Correlation Between CRISPR Therapeutics and Martin Marietta

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both CRISPR Therapeutics and Martin Marietta at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining CRISPR Therapeutics and Martin Marietta into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between CRISPR Therapeutics AG and Martin Marietta Materials, you can compare the effects of market volatilities on CRISPR Therapeutics and Martin Marietta and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in CRISPR Therapeutics with a short position of Martin Marietta. Check out your portfolio center. Please also check ongoing floating volatility patterns of CRISPR Therapeutics and Martin Marietta.

Diversification Opportunities for CRISPR Therapeutics and Martin Marietta

-0.33
  Correlation Coefficient

Very good diversification

The 3 months correlation between CRISPR and Martin is -0.33. Overlapping area represents the amount of risk that can be diversified away by holding CRISPR Therapeutics AG and Martin Marietta Materials in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Martin Marietta Materials and CRISPR Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on CRISPR Therapeutics AG are associated (or correlated) with Martin Marietta. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Martin Marietta Materials has no effect on the direction of CRISPR Therapeutics i.e., CRISPR Therapeutics and Martin Marietta go up and down completely randomly.

Pair Corralation between CRISPR Therapeutics and Martin Marietta

Assuming the 90 days trading horizon CRISPR Therapeutics AG is expected to generate 2.85 times more return on investment than Martin Marietta. However, CRISPR Therapeutics is 2.85 times more volatile than Martin Marietta Materials. It trades about 0.13 of its potential returns per unit of risk. Martin Marietta Materials is currently generating about 0.12 per unit of risk. If you would invest  4,080  in CRISPR Therapeutics AG on April 21, 2025 and sell it today you would earn a total of  1,470  from holding CRISPR Therapeutics AG or generate 36.03% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

CRISPR Therapeutics AG  vs.  Martin Marietta Materials

 Performance 
       Timeline  
CRISPR Therapeutics 

Risk-Adjusted Performance

OK

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in CRISPR Therapeutics AG are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively fragile basic indicators, CRISPR Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.
Martin Marietta Materials 

Risk-Adjusted Performance

OK

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Martin Marietta Materials are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Martin Marietta may actually be approaching a critical reversion point that can send shares even higher in August 2025.

CRISPR Therapeutics and Martin Marietta Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with CRISPR Therapeutics and Martin Marietta

The main advantage of trading using opposite CRISPR Therapeutics and Martin Marietta positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if CRISPR Therapeutics position performs unexpectedly, Martin Marietta can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Martin Marietta will offset losses from the drop in Martin Marietta's long position.
The idea behind CRISPR Therapeutics AG and Martin Marietta Materials pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Other Complementary Tools

Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance